National Psoriasis Foundation

US FDA approves high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm) injection, Boehringer Ingelheim's interchangeable* biosimilar to Humira®

Retrieved on: 
Mercredi, mai 1, 2024
FDA, Ulcerative colitis, Crohn's disease, Arthritis, Boehringer Ingelheim, News, Food, Patient, Psoriasis, National Psoriasis Foundation, Arthritis Foundation, Clinical trial, Pharmaceutical industry

"Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."

Key Points: 
  • "Many patients are treated with high-concentration adalimumab formulations, and we are excited to add this new option to our approved citrate-free Cyltezo and Adalimumab-adbm offerings."
  • "The flexibility of having multiple biosimilar formulations to choose from is important to support broader patient access to biologic medicines."
  • "We welcome the introduction of this additional formulation to expand the array of options available to our community."
  • The FDA approval is based, in part, on data from clinical trial VOLTAIRE-HCLF , a Phase I clinical trial comparing the bioavailability of high-concentration and low-concentration formulations of adalimumab-adbm.

AMERICAN SKIN ASSOCIATION ANNOUNCES NEW BOARD MEMBER JOSEPH F. MEROLA, MD, MMSc, FAAD, FACR

Retrieved on: 
Jeudi, avril 4, 2024
Cone Health Women's Hospital, Internal medicine, Patient, Skin, FAAD, Connective tissue, DSM-IV codes, Education, ASA, MDS, MMSc, Mass, Harvard Medical School, Associate, National Psoriasis Foundation, Psoriatic arthritis, Hospital, Public health, Atopic dermatitis, Dermatomyositis, Lupus, American Academy, Assessment, Management

NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.

Key Points: 
  • NEW YORK, April 4, 2024 /PRNewswire/ -- American Skin Association (ASA) announced today that Joseph F. Merola, MD, MMSc, FAAD, FACR, will join its Board of Directors.
  • Distinguished Chair in Dermatology and is Professor at the Peter O'Donnell Jr. School of Public Health.
  • "We are proud to announce the addition of Dr. Joseph Merola to ASA's Board of Directors.
  • He was recently elected to the Board of the American Academy of Dermatology.

LAURA GELLER BEAUTY FOUNDATION CELEBRATES 20 YEARS WITH NEW ACCOLADES AND CAMPAIGN

Retrieved on: 
Mercredi, janvier 31, 2024
Ageing, Heart, National Psoriasis Foundation, Let's Face It, QVC, Skin, Woman, NRS, Rosacea, Antioxidant, Beauty, National Rosacea Society, Face, Baking, Cosmetics

NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.

Key Points: 
  • NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Laura Geller Beauty, a pioneer in the makeup industry and known for artisan-crafted baked makeup, specifically formulated for mature skin, is celebrating its 20th-anniversary of its best-selling and cult-favorite product, Baked Balance-n-Brighten Color Correcting Foundation.
  • To mark this significant milestone, Laura Geller Beauty has launched the 'Let's Face It' campaign with a series of content to be leveraged across brand social channels and digital platforms.
  • "'Let's Face It' is an acknowledgment that we must change our beauty routines as we age," says Geller.
  • Laura Geller Beauty's products, including the best-selling Baked Balance-n-Brighten Color Correcting Foundation, are available on QVC, LauraGeller.com, Amazon, and other select retailers.

BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

Retrieved on: 
Mercredi, octobre 18, 2023
Science, Patient, FDA, UCB, National Psoriasis Foundation, Psoriasis, Week, Icahn School of Medicine at Mount Sinai, Plaque, Food, Observational study, MD, Information, Skin, Cytokine, BE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Bimekizumab, Jeff Flake, Mount Sinai, Adalimumab, Ustekinumab, Safety, Therapy, Pharmaceutical industry, Medical imaging, Dermatology, Medicine

"With BIMZELX now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S."

Key Points: 
  • "With BIMZELX now approved for psoriasis, we will move forward rapidly to submit applications for additional indications in the U.S."
    "We have been eagerly awaiting bimekizumab, the first IL-17A and IL-17F inhibitor, to be approved in the U.S. for the treatment of adults with moderate-to-severe plaque psoriasis.
  • "The approval of bimekizumab will provide an important new treatment option for adults living with moderate-to-severe plaque psoriasis," said Leah McCormick Howard, J.D., President and CEO for the National Psoriasis Foundation.
  • "Our hope is that new treatments translate into improved outcomes for many and help alleviate the physical and emotional burden of psoriasis."
  • For additional medical information, patient assistance or any other information, please call UCBCares® at 1-844-599-CARE (2273) or visit askucbcares.com .

FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Retrieved on: 
Vendredi, octobre 6, 2023
Irritant, Parent, Food, Doctor of Philosophy, Propylene glycol, Shanda, Silver, Caregiver, JD, Safety, Psoriasis, Disease, MUSE, FAAD, FDA, National Psoriasis Foundation, McGovern Medical School, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Skin, Child, Ethanol, Dermatology, Face, Excipient, Quality of life, Dietary supplement, Pharmaceutical industry, MD

ZORYVE, a once-daily, steroid-free cream that is effective, safe, and well tolerated, is designed to simplify management of plaque psoriasis.

Key Points: 
  • ZORYVE, a once-daily, steroid-free cream that is effective, safe, and well tolerated, is designed to simplify management of plaque psoriasis.
  • “ZORYVE has been shown to be safe, well tolerated, and effective; all critical factors for treating children with plaque psoriasis.
  • Plaques in sensitive areas, where the skin may be thinner or more sensitive, pose specific treatment challenges.
  • “In children, psoriasis ranges from mild to severe, and more often appears on sensitive areas including the face and skin folds, compared to adults.

BioTek reMEDys Calls for Increased Awareness Around Juvenile Arthritis Awareness and Education

Retrieved on: 
Mercredi, août 30, 2023
Women, Other Science, Research, Men, Family, Public Policy, Government, Other Health, Consumer, Teens, Other Communications, Healthcare Reform, Parenting, Human Resources, Communications, Professional Services, Other Education, Health, Education, Science, Other Consumer, National Psoriasis Foundation, Psoriasis, Hope, BioTek, Patient, Physician, Cognitive remediation therapy, Rare, Disease, Pharmaceutical industry

BioTek reMEDys is urging its clinical and patient constituents and the population at large to become more aware and get involved.

Key Points: 
  • BioTek reMEDys is urging its clinical and patient constituents and the population at large to become more aware and get involved.
  • To draw awareness to the condition, BioTek reMEDys is also encouraging people to share their experiences on the National Psoriasis Action Month website .
  • BioTek reMEDys is a multi-site national integrated infusion therapy provider focused on providing support to people with rare diseases.
  • Through supply chain management, innovative technology and trained specialty pharmacists, BioTek reMEDys is able to deliver superior service at a lower cost.

Bristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis

Retrieved on: 
Mardi, août 8, 2023
Biotechnology, Pharmaceutical, Health, Other Health, Injection, Bristol Myers Squibb, Psoriasis Area and Severity Index, Aphthous stomatitis, Mouth, Allergy, Face, Friends, Week, Chronic pain, Infection, CPU socket, Clear, American Academy, Acne, Multimedia, Inflammation, National Psoriasis Foundation, Psoriasis, BMY, Yale School of Medicine, Hyperkinesia, Light, Dermatology, Eyelid, Patient, AAD, Sinusitis, Immune system, Conditional sentence, TYK2, PASI, NPF, Glycine mollis, FDA, Rash, Family, Tongue, NYSE, Skin, Disease, Pharmaceutical industry, Deucravacitinib, Chronicon

View the full release here: https://www.businesswire.com/news/home/20230804756518/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230804756518/en/
    Nitika, living with moderate to severe plaque psoriasis.
  • (Photo: Bristol Myers Squibb)
    “I was young when I was diagnosed with moderate to severe plaque psoriasis, and it felt like my whole life revolved around my condition.
  • “This insight drove us to launch the Clear Understanding campaign to recognize those concessions and encourage people living with moderate to severe plaque psoriasis to talk to their dermatologist about available treatment options."
  • In two studies of moderate to severe plaque psoriasis, Sotyktu was compared to placebo and Otezla® (apremilast).

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Retrieved on: 
Samedi, juillet 1, 2023
Crohn's & Colitis Foundation, National Psoriasis Foundation, Psoriatic arthritis, Interchangeability, Arthritis Foundation, Food and Drug Administration, Dermatology, Quality of life, American Academy, Colitis, Psoriasis, Crohn's disease, Boehringer Ingelheim, Patient, Risk, Phase, FDA, Health, Safety, Food, Management of Crohn's disease, Rheumatoid arthritis, Disease, Generic drug, Pharmaceutical industry, Adalimumab

Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.

Key Points: 
  • Cyltezo was approved as an Interchangeable biosimilar in 2021, and is available as a prefilled syringe, or as a Cyltezo® Pen autoinjector.
  • "Cyltezo is the first and only FDA-approved Interchangeable biosimilar to Humira® that is available to the millions of people in the U.S. living with certain chronic inflammatory diseases," said Stephen Pagnotta, Executive Director and Biosimilar Commercial Lead at Boehringer Ingelheim.
  • An Interchangeable biosimilar must first meet the high FDA standards of a biosimilar.
  • "For many people living with plaque psoriasis or psoriatic arthritis, finding effective relief from symptoms can be a daily struggle.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
Lundi, juin 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹

Retrieved on: 
Jeudi, avril 27, 2023
Cream, National Psoriasis Foundation, Wake Forest School of Medicine, JDD, MC2, Novin, Scalp, Vitamin D, Psoriasis, Journal, Patient, Physician, Calcipotriol, Therapy, Pharmaceutical industry, Dermatology, Medicine

DURHAM, N.C. and COPENHAGEN, Denmark, April 27, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), and MC2 Therapeutics today announced that results of a recently conducted survey to assess psoriasis patients’ topical treatment experience, expectations, and preferences have been published in the Journal of Drugs in Dermatology (JDD). The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company. Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).

Key Points: 
  • The survey was conducted by the National Psoriasis Foundation and was sponsored by the Company.
  • Most of the participants self-reported having moderate psoriasis (83.9%); most were using systemic therapies (73.5%) and employing topical medications at least once per week (84%).
  • Understanding what factors impact adherence can help guide physicians in our choice of topical psoriasis treatments.” commented Steven R. Feldman, M.D., Ph.D., Professor of Dermatology, Wake Forest University School of Medicine.
  • “Findings from this survey demonstrated that psoriasis patients expect to see rapid improvement of their symptoms, or they report they will discontinue topical treatment.